10373 studies found for:    NCI
Show Display Options
Rank Status Study
21 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
22 Recruiting Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage I Follicular Thyroid Cancer;   Stage I Papillary Thyroid Cancer;   Stage II Follicular Thyroid Cancer;   Stage II Papillary Thyroid Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Papillary Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cediranib maleate;   Drug: lenalidomide;   Other: laboratory biomarker analysis
23 Completed Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
24 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: veliparib;   Drug: cisplatin;   Other: laboratory biomarker analysis
25 Completed Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant interferon alfa;   Biological: recombinant interleukin-12
26 Completed Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: carboplatin;   Drug: bortezomib
27 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: placebo;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
28 Completed GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Biological: GTI-2040;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
29 Completed Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Condition: Extensive Stage Small Cell Lung Cancer
Interventions: Biological: oblimersen sodium;   Drug: carboplatin;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis
30 Completed SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
Conditions: Atypical Squamous Cells of Undetermined Significance;   Cervical Cancer;   High-grade Squamous Intraepithelial Lesion;   Low-grade Squamous Intraepithelial Lesion
Interventions: Biological: HspE7;   Other: placebo;   Other: laboratory biomarker analysis
31 Active, not recruiting Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis;   Other: pharmacological study
32 Completed Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Conditions: Childhood Soft Tissue Sarcoma;   Childhood Liver Cancer;   Bone Cancer;   Brain Tumor;   Kidney Tumor
Intervention: Drug: doxorubicin HCl liposome
33 Active, not recruiting Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: alvocidib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
34 Active, not recruiting Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: azacitidine;   Drug: mitoxantrone hydrochloride;   Drug: etoposide;   Drug: cytarabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
35 Active, not recruiting Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
36 Completed Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
Conditions: Adult Fibrosarcoma;   Dermatofibrosarcoma Protuberans;   Recurrent Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
37 Completed Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Extra-adrenal Paraganglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Spinal Cord Neoplasm;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: Drug: vorinostat;   Drug: temozolomide;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
38 Suspended Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: bortezomib;   Other: laboratory biomarker analysis;   Other: questionnaire administration
39 Completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Stage II Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Procedure: adjuvant therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
40 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years